M Mehrabani1, M Najafi2, T Kamarul3, K Mansouri4, M Iranpour5, M H Nematollahi6, M Ghazi-Khansari7, A M Sharifi1,8. 1. Razi Drug Research Center, Department of pharmacology, Iran University of Medical Sciences, Tehran, Iran. 2. Department of Biochemistry, Iran University of Medical Sciences, Tehran, Iran. 3. Tissue Engineering Group (TEG) & Research, National Orthopedic Centre of Excellence in Research & Learning (NOCERAL), Department of Orthopedics, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. 4. Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. 5. Department of Pathology, Kerman University of Medical Sciences, Kerman, Iran. 6. Department of Biochemistry, Kerman University of Medical Sciences, Kerman, Iran. 7. Department of Pharmacology, Tehran University of Medical Sciences, Tehran, Iran. 8. Department of Tissue Engineering and regenerative Medicine, School of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran.
Abstract
OBJECTIVES: Both excessive and insufficient angiogenesis are associated with progression of diabetic complications, of which poor angiogenesis is an important feature. Currently, adipose-derived stem cells (ADSCs) are considered to be a promising source to aid therapeutic neovascularization. However, functionality of these cells is impaired by diabetes which can result from a defect in hypoxia-inducible factor-1 (HIF-1), a key mediator involved in neovascularization. In the current study, we sought to explore effectiveness of pharmacological priming with deferoxamine (DFO) as a hypoxia mimetic agent, to restore the compromised angiogenic pathway, with the aid of ADSCs derived from streptozotocin (STZ)-induced type 1 diabetic rats ('diabetic ADSCs'). MATERIALS AND METHODS: Diabetic ADSCs were treated with DFO and compared to normal and non-treated diabetic ADSCs for expression of HIF-1α, VEGF, FGF-2 and SDF-1, at mRNA and protein levels, using qRT-PCR, western blotting and ELISA assay. Activity of matrix metalloproteinases -2 and -9 were measured using a gelatin zymography assay. Angiogenic potential of conditioned media derived from normal, DFO-treated and non-treated diabetic ADSCs were determined by in vitro (in HUVECs) and in vivo experiments including scratch assay, three-dimensional tube formation testing and surgical wound healing models. RESULTS: DFO remarkably enhanced expression of noted genes by mRNA and protein levels and restored activity of matrix metalloproteinases -2 and -9. Compromised angiogenic potential of conditioned medium derived from diabetic ADSCs was restored by DFO both in vitro and in vivo experiments. CONCLUSION: DFO preconditioning restored neovascularization potential of ADSCs derived from diabetic rats by affecting the HIF-1α pathway.
OBJECTIVES: Both excessive and insufficient angiogenesis are associated with progression of diabetic complications, of which poor angiogenesis is an important feature. Currently, adipose-derived stem cells (ADSCs) are considered to be a promising source to aid therapeutic neovascularization. However, functionality of these cells is impaired by diabetes which can result from a defect in hypoxia-inducible factor-1 (HIF-1), a key mediator involved in neovascularization. In the current study, we sought to explore effectiveness of pharmacological priming with deferoxamine (DFO) as a hypoxia mimetic agent, to restore the compromised angiogenic pathway, with the aid of ADSCs derived from streptozotocin (STZ)-induced type 1 diabeticrats ('diabetic ADSCs'). MATERIALS AND METHODS:Diabetic ADSCs were treated with DFO and compared to normal and non-treated diabetic ADSCs for expression of HIF-1α, VEGF, FGF-2 and SDF-1, at mRNA and protein levels, using qRT-PCR, western blotting and ELISA assay. Activity of matrix metalloproteinases -2 and -9 were measured using a gelatin zymography assay. Angiogenic potential of conditioned media derived from normal, DFO-treated and non-treated diabetic ADSCs were determined by in vitro (in HUVECs) and in vivo experiments including scratch assay, three-dimensional tube formation testing and surgical wound healing models. RESULTS:DFO remarkably enhanced expression of noted genes by mRNA and protein levels and restored activity of matrix metalloproteinases -2 and -9. Compromised angiogenic potential of conditioned medium derived from diabetic ADSCs was restored by DFO both in vitro and in vivo experiments. CONCLUSION:DFO preconditioning restored neovascularization potential of ADSCs derived from diabeticrats by affecting the HIF-1α pathway.
Authors: Yoram Abramov; Barbara Golden; Megan Sullivan; Sylvia M Botros; Jay-James R Miller; Adeeb Alshahrour; Roger P Goldberg; Peter K Sand Journal: Wound Repair Regen Date: 2007 Jan-Feb Impact factor: 3.617
Authors: F Locatelli; A Bersano; E Ballabio; S Lanfranconi; D Papadimitriou; S Strazzer; N Bresolin; G P Comi; S Corti Journal: Cell Mol Life Sci Date: 2009-03 Impact factor: 9.261
Authors: Daniel J Ceradini; Anita R Kulkarni; Matthew J Callaghan; Oren M Tepper; Nicholas Bastidas; Mark E Kleinman; Jennifer M Capla; Robert D Galiano; Jamie P Levine; Geoffrey C Gurtner Journal: Nat Med Date: 2004-07-04 Impact factor: 53.440
Authors: Nina A Dzhoyashvili; Anastasia Yu Efimenko; Tatiana N Kochegura; Natalia I Kalinina; Natalia V Koptelova; Olga Yu Sukhareva; Marina V Shestakova; Renat S Akchurin; Vsevolod A Tkachuk; Yelena V Parfyonova Journal: J Transl Med Date: 2014-12-10 Impact factor: 5.531
Authors: Nicolás Toro-Urrego; Diego Julián Vesga-Jiménez; María Inés Herrera; Juan Pablo Luaces; Francisco Capani Journal: Curr Neuropharmacol Date: 2019 Impact factor: 7.363